14th Scientific Meeting

25th – 26th September 2014 Waldthausen/Mainz



CF related Basis Science Clinical CF Research

and results of research projects funded by the Mukoviszidose e.V.





Programme

Thursday, 25 September 2014

12:30 Opening	Stephan Kruip, Chairman Mukoviszidose e.V. Olaf Sommerburg, member of the scientific board of the Mukoviszidose e. V. (FGM)
CF related Basic	Science
Moderation:	Dominik Hartl (Tübingen, Germany) Michael Hogardt (Frankfurt, Germany)
12:40 - 01:00 pm	Characterization of the mechanosensitivity of CFTR
	Constanze Vitzthum (Gießen, Germany)
01:05 – 01:25 pm	Peptidic inhibitors to rescue delta F508-CFTR in Cystic Fibrosis
	Anja Heiduk (Berlin, Germany)
01:30 – 01:50 pm	Generation of disease-specific iPSCs and reporter cell lines for CF disease modeling and drug screening
	Madline Götz (Hannover, Germany)
01:55 – 02:15 pm	Impaired TLR4 and HIF expression in CF bronchial epithelial cells downregulates hemeoxygenase-1 and alters iron homeostasis in vitro
	Shashi Chillappagari (Marburg, Germany)
02:15 – 02:50 pm	Discussion & Coffee Break
02:50 – 03:10 pm	Antibiotic-free nanotherapeutics: Mucus- penetrating nanoparticles enhance pulmonary delivery and efficacy of quorum sensing inhibitors
	Nazende Günday Türeli (Marburg, Germany)
03:15 – 03:35 pm	CFTR gene engineering and CFTR repair N.N.

Clinical CF Research

Moderation:	Helge Hebestreit (Würzburg, Germany) Andreas Jung (Zürich, Switzerland)
03:40 – 04:00 pm	Antiviral activity of azithromycin in cystic fibrosis airway epithelial cells Marco Alves (Bern, Switzerland)
04:05 – 04:25 pm	Internet-based psychological support for parental caregivers: results of a pilot study Astrid Fidika (Ulm, Germany)
04:25 – 05:00 pm	Discussion & Coffee Break
05:00 – 05:20 pm	CF Research in the German Center for Lung Research Marcus Mall (Heidelberg, Germany)
05:25 – 05:45 pm	Functional CFTR Analysis for diagnosis and therapeutic monitoring in CF Nico Derichs (Berlin, Germany)
05:50 – 06:10 pm	Cystic fibrosis in Bulgaria: Challenges in diagnosis Ruslan Petrov (Varna, Bulgaria)
06:15 – 06:35 pm	Effects of dornase alfa and hypertonic saline on gas mixing in lung periphery in children with cystic fibrosis Florian Singer (Zurich, Switzerland)
06:35 – 07:00 pm	Discussion
07:30 pm	Dinner

Friday, 26 September 2014

CF Newborn Screening PAP based protocols

Moderation:	Olaf Sommerburg (Heidelberg, Germany) Frank Wissing (Bonn, Germany)
08:00 – 08:20 am	CF Neonatal Screening in Germany - Current Status and Implication for Patient Care? Olaf Sommerburg (Heidelberg, Germany)
08:25 – 08:45 am	Newborn Screening for CF in Northern Germany - first results of the process Sebastian Schmidt (Greifswald, Germany)
08:50 – 09:10 am	Newborn screening for Cystic Fibrosis with IRT- PAP-DNA-sequencing : 3 year experience with nation-wide screening in the Netherlands
09:15 – 09:35 am	Jeanette E. Dankert-Roelse (Klimmen, Netherlands) IRT-PAP-Screening: Evaluation of a new Cut Off-Model Jutta Hammermann (Dresden, Germany)
09:40 – 10:00 am	IRT-PAP protocol: the French experience Jacques Sarles (Marseille, France)
10:00 - 10:30 am	Discussion & Coffee Break

CF Newborn Screening

Moderation:	Olaf Sommerburg (Heidelberg, Germany) Frank Wissing (Bonn, Germany)
10:30 – 10:50 am	Ensuring optimal outcomes from newborn screening for CF Kevin Southern (Liverpool, UK)
10:55 – 10:15 am	Quality assurance Jürg Barben (St. Gallen, Switzerland)
10:20 – 11:40 am	MRI in infants and preschool children with CF Mark O. Wielpütz (Heidelberg, Germany)

11:45 – 12:05 pm	Sensitive Chest CT related outcome measures in early lung Disease Harm Tiddens (Rotterdam, Netherlands)
12:10 – 12:30 pm	MBW – pulmonary function test for infants? Mirjam Stahl (Heidelberg, Germany)
12:35 - 01:00 pm	Discussion
01:00 pm	Closing of the meeting Lunch Snack

01:30 pm Consensus Meeting on PAP-based protocols for CF newborn Screening ECFS Neonatal Screening Working Group (invited persons only, for invitation please contact Olaf.Sommerburg@med.uni-heidelberg.de)

Moderation:	Kevin Southern (Liverpool, UK)
	Jutta Bend (Bonn, Germany)

The Scientific Meeting is supported by



∕X⊕Forest





Sponsors: Novartis Pharma GmbH/4.500,00 €; Forest Laboratories Deutschland GmbH/3.000,00 €; Vertex Parmaceuticals (Germany) GmbH/3.000,00 €, Gilead Sciences GmbH/3.000,00 €